Cargando…

Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN

SIMPLE SUMMARY: In patients with relapsed or metastasized squamous cell cancer of the head and neck (R/M SCCHN), the PD-L1 Combined Positive Score (CPS) is currently the only predictive biomarker for treatment with anti-PD-1 agents. However, ambiguous results have been determined regarding the overa...

Descripción completa

Detalles Bibliográficos
Autores principales: De Keukeleire, Stijn Jeroen, Vermassen, Tijl, Deron, Philippe, Huvenne, Wouter, Duprez, Fréderic, Creytens, David, Van Dorpe, Jo, Ferdinande, Liesbeth, Rottey, Sylvie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139955/
https://www.ncbi.nlm.nih.gov/pubmed/35626035
http://dx.doi.org/10.3390/cancers14102431
_version_ 1784714981771575296
author De Keukeleire, Stijn Jeroen
Vermassen, Tijl
Deron, Philippe
Huvenne, Wouter
Duprez, Fréderic
Creytens, David
Van Dorpe, Jo
Ferdinande, Liesbeth
Rottey, Sylvie
author_facet De Keukeleire, Stijn Jeroen
Vermassen, Tijl
Deron, Philippe
Huvenne, Wouter
Duprez, Fréderic
Creytens, David
Van Dorpe, Jo
Ferdinande, Liesbeth
Rottey, Sylvie
author_sort De Keukeleire, Stijn Jeroen
collection PubMed
description SIMPLE SUMMARY: In patients with relapsed or metastasized squamous cell cancer of the head and neck (R/M SCCHN), the PD-L1 Combined Positive Score (CPS) is currently the only predictive biomarker for treatment with anti-PD-1 agents. However, ambiguous results have been determined regarding the overall response rates of immunotherapeutic agents based on PD-L1 status, which may be partially attributed to spatiotemporal heterogeneity. Furthermore, tumor-infiltrating lymphocytes (TILs) have proven to be of significant prognostic value, yet lack of a standardized method for quantification impedes their integration into the current armamentarium of biomarkers in SCCHN. In this paper, concordance of PD-L1 CPS and stromal TILs was investigated in different paired samples of SCCHN subtypes. The results were then linked to well-known clinicopathological variables and prognosis. ABSTRACT: Background: The clinical significance of tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression has been thoroughly researched in squamous cell carcinoma of the head and neck (SCCHN). To address the impact of intra- and intertumoral heterogeneity in these biomarkers, we explored the concordance of PD-L1 combined positive score (CPS) and stromal TILs in different paired tissue sample types, while evaluating their internal relationship and prognostic impact. Methods: A total of 165 tissue blocks from 80 SCCHN patients were reviewed for TILs and PD-L1 CPS. Concordance between paired tissue samples was evaluated, and their association with several clinicopathological variables, overall survival (OS), and disease-free survival (DFS) was determined. Results: Biopsies and paired resection material were severely discordant in 39% and 34% of samples for CPS and TIL count, respectively, of which CPS was underscored in 27% of biopsies. In paired primary tumor–metastatic lesions, the disagreement was lower for CPS (19%) but not for TIL count (44%). PD-L1 CPS was correlated with prolonged OS when calculated from tissue acquirement, while extended OS and DFS were observed for high TIL density. Conclusion: Intertumoral and, especially, intratumoral heterogeneity were confounding factors when determining PD-L1 CPS and TIL count on paired tissue samples, indicating the increasing necessity of assessing both biomarkers on representative tissue material. Although TILs hold valuable prognostic information in SCCHN, the robustness of PD-L1 as a biomarker in SCCHN remains ambiguous.
format Online
Article
Text
id pubmed-9139955
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91399552022-05-28 Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN De Keukeleire, Stijn Jeroen Vermassen, Tijl Deron, Philippe Huvenne, Wouter Duprez, Fréderic Creytens, David Van Dorpe, Jo Ferdinande, Liesbeth Rottey, Sylvie Cancers (Basel) Article SIMPLE SUMMARY: In patients with relapsed or metastasized squamous cell cancer of the head and neck (R/M SCCHN), the PD-L1 Combined Positive Score (CPS) is currently the only predictive biomarker for treatment with anti-PD-1 agents. However, ambiguous results have been determined regarding the overall response rates of immunotherapeutic agents based on PD-L1 status, which may be partially attributed to spatiotemporal heterogeneity. Furthermore, tumor-infiltrating lymphocytes (TILs) have proven to be of significant prognostic value, yet lack of a standardized method for quantification impedes their integration into the current armamentarium of biomarkers in SCCHN. In this paper, concordance of PD-L1 CPS and stromal TILs was investigated in different paired samples of SCCHN subtypes. The results were then linked to well-known clinicopathological variables and prognosis. ABSTRACT: Background: The clinical significance of tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression has been thoroughly researched in squamous cell carcinoma of the head and neck (SCCHN). To address the impact of intra- and intertumoral heterogeneity in these biomarkers, we explored the concordance of PD-L1 combined positive score (CPS) and stromal TILs in different paired tissue sample types, while evaluating their internal relationship and prognostic impact. Methods: A total of 165 tissue blocks from 80 SCCHN patients were reviewed for TILs and PD-L1 CPS. Concordance between paired tissue samples was evaluated, and their association with several clinicopathological variables, overall survival (OS), and disease-free survival (DFS) was determined. Results: Biopsies and paired resection material were severely discordant in 39% and 34% of samples for CPS and TIL count, respectively, of which CPS was underscored in 27% of biopsies. In paired primary tumor–metastatic lesions, the disagreement was lower for CPS (19%) but not for TIL count (44%). PD-L1 CPS was correlated with prolonged OS when calculated from tissue acquirement, while extended OS and DFS were observed for high TIL density. Conclusion: Intertumoral and, especially, intratumoral heterogeneity were confounding factors when determining PD-L1 CPS and TIL count on paired tissue samples, indicating the increasing necessity of assessing both biomarkers on representative tissue material. Although TILs hold valuable prognostic information in SCCHN, the robustness of PD-L1 as a biomarker in SCCHN remains ambiguous. MDPI 2022-05-14 /pmc/articles/PMC9139955/ /pubmed/35626035 http://dx.doi.org/10.3390/cancers14102431 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
De Keukeleire, Stijn Jeroen
Vermassen, Tijl
Deron, Philippe
Huvenne, Wouter
Duprez, Fréderic
Creytens, David
Van Dorpe, Jo
Ferdinande, Liesbeth
Rottey, Sylvie
Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
title Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
title_full Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
title_fullStr Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
title_full_unstemmed Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
title_short Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
title_sort concordance, correlation, and clinical impact of standardized pd-l1 and til scoring in scchn
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139955/
https://www.ncbi.nlm.nih.gov/pubmed/35626035
http://dx.doi.org/10.3390/cancers14102431
work_keys_str_mv AT dekeukeleirestijnjeroen concordancecorrelationandclinicalimpactofstandardizedpdl1andtilscoringinscchn
AT vermassentijl concordancecorrelationandclinicalimpactofstandardizedpdl1andtilscoringinscchn
AT deronphilippe concordancecorrelationandclinicalimpactofstandardizedpdl1andtilscoringinscchn
AT huvennewouter concordancecorrelationandclinicalimpactofstandardizedpdl1andtilscoringinscchn
AT duprezfrederic concordancecorrelationandclinicalimpactofstandardizedpdl1andtilscoringinscchn
AT creytensdavid concordancecorrelationandclinicalimpactofstandardizedpdl1andtilscoringinscchn
AT vandorpejo concordancecorrelationandclinicalimpactofstandardizedpdl1andtilscoringinscchn
AT ferdinandeliesbeth concordancecorrelationandclinicalimpactofstandardizedpdl1andtilscoringinscchn
AT rotteysylvie concordancecorrelationandclinicalimpactofstandardizedpdl1andtilscoringinscchn